Introduction of
20501-56-8
:
Talatisamine is an orally active cyclophilin D activator isolated from the roots of Aconitum carmichaeli Debx. Talatisamine exerts biological functions by activating cyclophilin D, inhibiting Ca2+-dependent opening of the mitochondrial permeability transition pore (mPTP) (IC50=78 μM), and blocking delayed rectifier K+ channels (IC50=146 μM). Talatisamine possesses both antioxidant and membrane-stabilizing properties, effectively inhibits lipid peroxidation and protects mitochondrial membrane function. Talatisamine exhibits multiple activities including antiarrhythmic, hypotensive, anti-inflammatory, anticancer and neuroprotective effects. Talatisamine finds applications in the research of ischemic diseases, rheumatoid arthritis, inflammation-related diseases and Alzheimer's disease[1][2][3].
In Vitro:Talatisamine (10-200 μM) inhibits Ca
2+-dependent mPTP opening in isolated rat liver mitochondria in a concentration-dependent manner, with an IC
50 of 78 μM
[1].
Talatisamine (10-200 μM) inhibits Ca
2+-dependent mPTP opening in isolated rat heart mitochondria in a concentration-dependent manner in vitro, and its activity is weaker than that in rat liver mitochondria
[1].
Talatisamine (10-200 μM) exhibits enhanced concentration-dependent inhibition of Ca
2+-dependent mPTP opening in isolated rat liver mitochondria in the presence of cyclosporin A (CsA)
[1].
Talatisamine (50-200 μM) inhibits Fe
2+/ascorbic acid-induced MDA production in isolated rat liver mitochondria in vitro in a concentration-dependent manner
[1].
Talatisamine (10-100 μM) inhibits Fe
2+/ascorbic acid-induced lipid peroxidation (LPO) in isolated rat liver mitochondria in a concentration-dependent manner in vitro, with the maximum inhibitory effect observed at 100 μM
[1].
Talatisamine exhibits no inhibitory effect on voltage-gated Na
+ or Ca
2+ currents at concentrations up to 3 mM
[2].
In Vivo:Talatisamine (1 mg/kg; i.v.; single dose; 2-8 mg/kg; p.o.; single dose) exhibits rapid elimination in male ICR mice following intravenous or oral administration, with absolute oral bioavailability ranging from 65.0% to 79.2% across tested doses
[2].
Your information is safe with us.